Cyto-IL-15 synergizes with the STING agonist ADU-S100 to eliminate prostate tumors and confer durable immunity in mouse models

INTRODUCTION: Prostate cancer is one of the most commonly diagnosed malignancies in men with high mortality rates. Despite the recent therapeutic advances, such as immunotherapies, survival of patients with advance disease remains significantly low. Blockade of immune checkpoints has led to low resp...

Descripción completa

Detalles Bibliográficos
Autores principales: Papaevangelou, Efthymia, Esteves, Ana M., Dasgupta, Prokar, Galustian, Christine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10350564/
https://www.ncbi.nlm.nih.gov/pubmed/37465665
http://dx.doi.org/10.3389/fimmu.2023.1196829

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10350564/
https://www.ncbi.nlm.nih.gov/pubmed/37465665
http://dx.doi.org/10.3389/fimmu.2023.1196829

Ejemplares similares